In the latest trading session, 0.69 million Autolus Therapeutics plc ADR (NASDAQ:AUTL) shares changed hands as the company’s beta touched 2.04. With the company’s most recent per share price at $2.18 changing hands around $0.0 or 0.00% at last look, the market valuation stands at $580.14M. AUTL’s current price is a discount, trading about -241.74% off its 52-week high of $7.45. The share price had its 52-week low at $2.16, which suggests the last value was 0.92% up since then. When we look at Autolus Therapeutics plc ADR’s average trading volume, we note the 10-day average is 2.22 million shares, with the 3-month average coming to 1.75 million.
Analysts gave the Autolus Therapeutics plc ADR (AUTL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended AUTL as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Autolus Therapeutics plc ADR’s EPS for the current quarter is expected to be -0.22.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
The company’s shares are showing year-to-date downside of -66.15%, with the 5-day performance at -12.45% in the red. However, in the 30-day time frame, Autolus Therapeutics plc ADR (NASDAQ:AUTL) is -25.85% down. Looking at the short shares, we see there were 6.29 million shares sold at short interest cover period of 2.48 days.
The consensus price target for the stock as assigned by Wall Street analysts is 7.6, meaning bulls need an upside of 71.32% from its recent market value. According to analyst projections, AUTL’s forecast low is 7.6 with 7.6 as the target high. To hit the forecast high, the stock’s price needs a -248.62% plunge from its current level, while the stock would need to soar -248.62% for it to hit the projected low.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
Data shows that the Autolus Therapeutics plc ADR share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -35.12% over the past 6 months, a 21.67% in annual growth rate that is considerably higher than the industry average of 16.70%. Year-over-year growth is forecast to reach 920.38% up from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 2.98M. 1 analysts are of the opinion that Autolus Therapeutics plc ADR’s revenue for the current quarter will be 17.52M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 73.59%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 3.32%. The 2024 estimates are for Autolus Therapeutics plc ADR earnings to increase by 24.87%.
AUTL Dividends
Autolus Therapeutics plc ADR is expected to release its next quarterly earnings report in January.
Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s Major holders
BLACKSTONE INC. holds the second largest percentage of outstanding shares, with 9.2207% or 20.49 million shares worth $71.29 million as of 2024-06-30.
